Fig. 4: PDZK1 protein is specifically decreased in TNBC tissues and negatively correlated with the degree of TNBC malignancy.
From: PDZK1 suppresses TNBC development and sensitizes TNBC cells to erlotinib via the EGFR pathway
A PDZK1 protein level was downregulated in TNBC tissues. Representative IHC figure of PDZK1 expression in adjacent normal tissues and TNBC tissues. B Scatter plot displaying the expression of PDZK1 in adjacent normal tissues and TNBC tissues. C PDZK1 protein level was downregulated gradually as T stage progressed. D PDZK1 protein level was correlated with TNBC tumour volume. E PDZK1 protein level was correlated with TNBC lymph node metastasis. F K-M curve of TNBC patients. TNBC patients were divided into high and low groups according to the median value of PDZK1 protein level. Data were presented as mean ± SD. Data were analysed by Student’s two-tailed t-test (B, D, E) and ANOVA (C). Survival curves were calculated by Kaplan–Meier methods. *P < 0.05, ***P < 0.001, ****P < 0.0001.
